The claim
“RSP is a buy as the equal-weight S&P 500 benefits from valuation convergence with the Mag 7, supported by convergence in margins and productivity.”
Why he says it — point by point
FAVORABLE & AGAINST · BOTH KEPTWhy
since last fall we've been short mag seven, long basically everything else global equities, the non mag seven companies here in the US market as a function of our source of funds theme. Again, we're going to see a convergence in productivity, profitability, margins, and ultimately value weight.
we're going to continue to see a convergence of the valuations between basically everything else relative to the mag seven
we think that trade has legs.
The structured call
Direction
Bullish
Catalyst
—
Target
—
The receipt
Publish-day price $$204.10 · the claim is anchored to the moment it was said.